AGI Therapeutics to present at Cowen and Company 28th Annual Health Care Conference in Boston -- 4.45 p.m., Monday 17 March, 2008 -- Dublin, Ireland, 5 March 2008 - AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces that the Company's President of U.S. Operations, Dr. David Young, and Chief Financial Officer, David Kelly, will make a presentation at the Cowen and Company 28th Annual Health Care Conference in Boston. The conference will be held at the Boston Marriott, Copley Place. AGI will present on Monday 17 March at 4.45 p.m. EST (9.45 p.m. GMT). A copy of the presentation will be available after the event on the AGI website at www.agitherapeutics.com under the "Investors: Publications" tab. Contact Information: AGI Therapeutics plc. Tel: +353 1 449 3254 David Kelly, Chief Financial Officer Financial Dynamics - UK Tel: +44 (0) 20 7269 7182 Deborah Scott/Lara Mott Financial Dynamics - Ireland Tel: +353 1 663 3607 Aisling Garvey Notes to Editors: About AGI Therapeutics plc AGI is a speciality pharmaceutical company which is focused on the development and commercialisation of differentiated drug products for gastrointestinal (GI) diseases and disorders. AGI's common shares are listed on the Alternative Investment Market of the London Stock Exchange (AIM) and on the Irish Enterprise Exchange of the Irish Stock Market (IEX) as AGI. The Company has a portfolio of product candidates derived from its Known Molecular Entity (KME) approach to drug re-profiling and development. The Company's lead product candidate, Rezular, is an orally administered triple-action intestinal regulator, a first-in-class mechanism for the treatment of Diarrhoea predominant Irritable Bowel Syndrome, (IBS-D). Rezular is currently in Phase III clinical trials. KME is a re-profiling methodology used by the Company to identify existing therapeutic drugs which typically have been marketed for a number of years, have established safety profiles and can be developed for new clinical indications or with improved profiles in their existing clinical indications. In this way, the Company seeks to reduce the risk, time and cost of new product development as compared to the development of new chemical entities. AGI is developing a range of product candidates to treat a variety of prevalent GI diseases and disorders, including irritable bowel syndrome (IBS), dyspepsia, gastroparesis, ulcerative colitis, gastro-esophageal reflux disease (GERD) and diarrhoea-related conditions such as chemotherapy-induced diarrhoea (CID). The Company is targeting areas of the GI therapeutic drug products market for its product candidates where there are currently unmet medical needs or where the effectiveness of existing drug therapies can be further improved. The Company has five active clinical stage product candidates which are either isomers or new drug delivery formulations of existing approved drugs, and which have established safety and tolerability profiles in their currently approved clinical indications. For further information please see www.agitherapeutics.com Statements contained within this press release may contain forward-looking comments which involve risks and uncertainties that may cause actual results to vary from those contained in the forward-looking statements. In some cases, you can identify such forward-looking statements by terminology such as 'may', ' will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', ' estimates', 'predicts', 'potential', or 'continue'. Predictions and forward-looking references in this press release are subject to the satisfactory progress of research which is, by nature, unpredictable. Forward projections reflect management's best estimates based on information available at the time of issue. This information is provided by RNS The company news service from the London Stock Exchange END
AGI Therapeutics Plc announces Cowen Healthcare Conference
| Source: AGI Therapeutics plc
Dublin, Ireland--(Marketwire - March 5, 2008) -